Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

Saved in:

Bibliographic Details
Published in	Haematologica (Roma) Vol. 109; no. 7; pp. 2284 - 2289
Main Authors	Xu, Linlin, Shadman, Mazyar, Flinn, Ian W., Levy, Moshe Y., Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte A., Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul D., Crescenzo, Rocco, By, Kunthel, Cohen, Aileen, Chen, Dih-Yih, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P., Ramakrishnan, Vanitha
Format	Journal Article
Language	English
Published	Italy Fondazione Ferrata Storti 01.07.2024 Ferrata Storti Foundation
Subjects	Adenine - analogs & derivatives Aged Aminobutyrates - adverse effects Aminobutyrates - therapeutic use Benzamides - therapeutic use Female Genomics - methods Humans Letter to the Editor Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Middle Aged Mutation Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazines - administration & dosage Pyrazines - adverse effects Pyrazines - therapeutic use Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Thiazoles - administration & dosage Thiazoles - adverse effects Thiazoles - therapeutic use
Online Access	Get full text

Cover

Loading…

More Information
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 MS, IWF, MYL, RP, JMB, SFZ, JLC, JM, ECK, HAY, BF, AC, PKT, MDG, SM, and JPS enrolled patients and collected clinical data. LX, RC, KB, AC, D-YC, AI, and VR contributed to the intellectual content, conception, and design of the study. LX and KB processed data, analyzed statistics, generated figures, and wrote the manuscript. All authors contributed to data interpretation and revised the manuscript. Disclosures Contributions The study protocol was developed by BeiGene, Ltd. in collaboration with the study investigators. BeiGene was also involved in data collection, analysis, and interpretation of results. Statistical analyses were performed by statisticians at BeiGene. LX, RC, KB, AC, AI, and VR are employees of and hold stock/shares in BeiGene Co. MS is a consultant for AbbVie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, BeiGene, Bristol Myers Squibb, Morphosys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate Therapeutics, MEI Pharma, and Atara Biotherapeutics, and receives research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Sunesis, Atara Biotherapeutics, Genmab, and Morphosys/Incyte. IF is a member of a board of directors or advisory committees at Vincerx. ML receives consulting fees from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, GSK, Incyte, Janssen, Karyopharm, Kite, Lilly, Sanofi, Seagen, and Takeda, payment or honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, GSK, Incyte, Janssen, Karyopharm, Kite, Lilly, Sanofi, Seagen, and Takeda, travel support from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Genmab, GSK, Incyte, Janssen, Karyopharm, Kite, Lilly, Sanofi, Seagen, and Takeda, and has a leadership or fiduciary role from Sellas. JMB receives consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Constellation, Eli Lilly, Epizyme, Foresight, Genentech, Genmab, Kura, Kymera, Morphosys, Novartis, Nurix, TG Therapeutics, Verastem, and X4 Pharmaceuticals and receives payments/honoraria from Seagen and BeiGene. SFZ receives honorarium from Bristol Myers Squibb, Immunosome, and AbbVie. MDG receives honoraria from Karyopharm, TG Therapeutics, Janssen, and GSK. RC has equity with Pfizer and GSK and individual stocks in SAGA Diagnostics. D-YC has equity with BeiGene. JPS receives consulting fees from TG Therapeutics, Genentech, AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, and Merck, and research funds from Genentech, Celgene, Gilead Sciences, TG Therapeutics, Merck, and Takeda.
ISSN:	0390-6078 1592-8721 1592-8721
DOI:	10.3324/haematol.2023.283861